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Abstract
We investigated the effects of chronic mineralocorticoid receptor blockade with eplerenone on the development and
progression of hypertension and end organ damage in Dahl salt-sensitive rats. Eplerenone signiﬁcantly attenuated the
progressive rise in systolic blood pressure (SBP) (204 ± 3 vs. 179±3 mmHg, p < 0.05), reduced proteinuria (605.5 ±
29.6 vs. 479.7 ± 26.1 mg/24h, p < 0.05), improved injury scores of glomeruli, tubules, renal interstitium, and vas-
culature in Dahl salt-sensitive rats fed a high-salt diet. These results demonstrate that mineralocorticoid receptor
antagonism provides target organ protection and attenuates the development of elevated blood pressure (BP) in a
model of salt-sensitive hypertension.
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INTRODUCTION
Aldosterone plays a critical role in regulating body
ﬂuid, electrolytes, and blood pressure (BP) homeosta-
sis, which is achieved by promoting the reabsorption
of sodium and water and the secretion of potas-
sium in the connecting tubules and collecting ducts
in the kidneys. Accumulated evidence suggests that
mineralocorticoid receptor (MR) activation mediated
by increased aldosterone plays a crucial role in the
development and progression of hypertension and end
organ damage (1–3). Extensive animal and clinical stud-
ies have demonstrated that MR antagonism lowers BP
(4–11) and provides cardiac, vascular, and renal pro-
tection via both hemodynamic and non-hemodynamic
mechanisms (5–8,11–16). Moreover, the Eplerenone
Post-Acute Myocardial Infarction Heart Failure Efﬁ-
cacy and Survival Study (EPHESUS) demonstrated the
addition of eplerenone, a selective MR antagonist, to
standard medical therapy reduced morbidity and mor-
tality among patients with acute myocardial infarction
complicated by left ventricular dysfunction and heart
failure (17).
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Hypertension affects approximately 50 million indi-
viduals in the United States (18) and approximately
1 billion people worldwide (19). A substantial propor-
tion of individuals with hypertension in industrialized
countries consume high levels of salt and Weinberger
reported that approximately 50% of individuals with
essential hypertension are salt-sensitive (20). Abnormal-
ities in aldosterone-mediated MR activation are asso-
ciated with salt-sensitivity and hypertension (21–25).
The Dahl salt-sensitive (Dahl SS) rat, a rodent model
of salt-sensitive hypertension, has been widely used
to investigate the molecular mechanisms underlying
the development of salt-induced hypertension and to
evaluate the efﬁcacy of pharmacologic interventions in
salt-sensitive hypertension (26–30). The selective MR
antagonist, eplerenone, has been evaluated extensively
in Dahl SS rats on a high-salt diet. However, reports
on its efﬁcacy for lowering BP were diverse: some stud-
ies reported a marked attenuation of the increase in BP
(4,7,8), whereas other studies reported no effects on BP
in response to salt-loading in Dahl SS rats (14,15).
Importantly, none of these studies have
comprehensively investigated the effects of eplerenone
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on indices of end organ damage. In addition, few stud-
ies have assessed the BP lowering efﬁcacy of eplerenone
in Dahl SS rats on low-salt diet. To this end, the present
study was designed to evaluate the effects of chronic
MR antagonism with eplerenone on the development
and progression of hypertension using radiotelemetry
and to assess the effects of eplerenone on end organ
structure and function and renal injury biomarkers in
Dahl SS rats maintained on high- or low-salt diets.
MATERIALS AND METHODS
Dahl SS rats (Harlan Labs. Inc: Indianapolis, IN, USA)
were housed in a temperature- and humidity-controlled
room with a 12:12-h dark-light cycle with food and
water provided ad libitum. Rodent diets (#7034, low-
salt diet, containing 0.3% NaCl; TD.92034, high-salt
diet, containing 4% NaCl) were purchased from Har-
lan Teklad (Madison, WI, USA). Eplerenone, puriﬁed
from Inspra tablets (Pﬁzer Inc., New York, NY, USA)
was used to prepare eplerenone-medicated diets (based
on Harlan Tekald #7034 and TD.92034) by Research
Diets, Inc. (New Brunswick, NJ, USA). The eplerenone
concentration in the diet was calculated to give a daily
dose of 100 mg·kg−1d−1 eplerenone based on food
intake relative to body weight.
All procedures utilizing experimental animals were
conducted in accordance with the Guide for the Care
and Use of Laboratory Animals, and experimental pro-
tocols were approved in advance by the Institutional
Animal Care and Use Committee at Merck Research
Laboratories, Rahway, NJ.
Radiotelemetry Implant Surgery
Male Dahl SS rats (15 weeks old) were anesthetized
with isoﬂurane and premedicated with buprenor-
phine (0.03 mg·kg−1, s.c.: Reckitt Benckiser healthcare
Ltd., Hull, UK) prior to surgery. Telemetry devices
(TA11PA-C40, Data Sciences International, DSI, St.
Paul, MN, USA) were aseptically placed in a subcuta-
neous pocket on one side of the body with the catheter
inserted into the descending aorta via the femoral artery.
Penicillin G (150,000 U·kg−1,s . c .B i m e d aI n c . ,I r w i n -
dale, CA, USA) was administered at the end of surgery.
Rats were allowed to recover for 2 to 3 weeks prior to
experimentation.
Experimental Design
Dahl SS rats with implanted radiotelemetry devices
were housed individually in Nalgene metabolism cages
(Braintree Scientiﬁc, Inc., Braintree, MA, USA) fol-
lowing a 1-week acclimation period. All animals were
maintained on Harlan Teklad diet #7034 (0.3% NaCl)
prior to study. The rats were randomly divided into four
groups: Group 1, low-salt diet (0.3% NaCl), n = 8;
Group 2, low-salt diet plus eplerenone 100 mg·kg−1d−1,
n = 8; Group 3, high-salt diet (4% NaCl), n = 8; Group
4, high-salt diet plus eplerenone 100 mg·kg−1d−1,n=
8. Animals were maintained in these treatment groups
for an 8-week period.
BP Measurement, Renal Function Assessment, and
Kidney Injury Biomarkers Detection
Radiotelemetry signals were collected and analyzed
using a DSI Dataquest System Version 4.1 (Data Sci-
ences International, DSI, St. Paul, MN, USA). Mean,
systolic, diastolic, and pulse arterial BPs and heart rate
were determined on a beat-by-beat basis. Data was col-
lected for 30 min every hour and was reported as aver-
age values for each animal over a 24-h period. Twenty-
four hour food and water intake and urine output were
monitored once a week during the study. Urinary elec-
trolytes (including Na, K, and Cl), creatinine, and
protein concentration were assessed by a Roche Mod-
ular Chemistry System (Roche Diagnostics, Indianapo-
lis, IN, USA). Kidney injury biomarkers including
lipocalin-2 (LPN), osteopontin (OPN), kidney injury
molecule-1 (KIM-1), and renal papillary antigen 1
(RPA-1) were detected using a Kidney Injury Panel
1(rat) kit and Argutus AKI (rat) kit from Meso Scale
Discovery, LLC (Gaithersburg, MA, USA). All these
biomarkers have been validated in animal studies (31).
Serum Aldosterone, Plasma Electrolytes, Creatinine,
and Eplerenone Concentration Measurement
Upon study termination, blood was collected by jugu-
lar venepuncture from conscious animals and was used
for measuring serum aldosterone by ELISA (IBL, Ham-
burg, Germany). Thereafter, animals were euthanized
by CO2 inhalation and cardiac puncture was per-
formed to collect blood for determination of plasma
electrolytes and creatinine (Roche Diagnostics, Indi-
anapolis, IN, USA) and eplerenone levels (determined
by LC/MS/MS following protein precipitation with ace-
tonitrile).
Histopathology
Kidney and heart tissues were harvested from all ani-
mals, ﬁxed in Prefer (Anatech LTD., Battle Creek, MI,
USA) for at least 24 h, and were parafﬁn-embedded.
Tissue sections were stained with hematoxylin and eosin
(H&E) and the heart also with Masson’s trichrome
strain (for collagen). The severity of histopathologic
changes in renal tubules, interstitium, vasculature, and
glomeruli were graded on a 1 to 5 scale correspond-
ing to minimal, mild, moderate, marked, and severe
(32). Sections from both kidneys were examined and
the ﬁnal scores composite are a composite from all sec-
tions of each slice. Separate deparafﬁnized heart tissue
sections were stained with Masson trichrome, which
stains collagen-enriched areas as blue and cellular ele-
ments as red. Collagen deposition in the ventricle wall
and perivascular area was graded on a 1 to 5 scale cor-
responding to minimal, mild, moderate, marked, and
severe, based on the blue stained area size and intensity.
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Statistical Analyses
All data are presented as means ± standard error of
the mean (SE). A repeated measure analysis of variance
(rmANOVA) was used for time course data analysis.
One-way ANOVA followed by Newman-Keuls post-hoc
test was used for comparisons of only one time point
values in all groups. P value of <0.05 was considered to
be of statistical signiﬁcance.
RESULTS
Effects of Eplerenone on Blood Pressure and Heart Rate
The baseline SBP of Dahl SS rats, while maintained on
a low (0.3% NaCl) dietary salt and measured 2 to 3
weeks post-implantation of telemetry devices, was 151
± 3 mmHg (Figure 1). Systolic BP gradually increased
by 18 ± 3 mmHg over the subsequent 8 weeks (from
age 18 weeks to 25 weeks). This increase reﬂects the
spontaneous development of hypertension characteris-
tic of this rat strain. As expected, consumption of a
high-salt (4% NaCl) diet accelerated the progression of
hypertension. Thus, SBP increased by 52 ± 2 mmHg
from 152 ± 3 mmHg to 204 ± 3 mmHg over an 8-
week period of high-salt feeding. The extent of BP
elevation in response to a high-salt diet was similar
when measured during the day and night periods (data
not shown). Chronic treatment with eplerenone (100
mg·kg−1d−1) completely blocked the SBP increase in
animals fed a low-salt diet (170 ± 5 mmHg vs.154
± 3 mmHg, p < 0.05) and signiﬁcantly blunted the
progression of hypertension in animals fed a high-salt
diet (204 ± 3 mmHg vs.179 ± 3 mmHg, p < 0.05)
(Figure 1). Heart rates declined by less than 10% dur-
ing the course of study and for the most part were not
signiﬁcantly different among groups receiving low or
high salt diet with or without eplerenone (Figure 1).
There was a small increase in heart rate during the last
3 weeks for those animals on the high-salt diet that was
not apparent in those animals receiving high salt plus
eplerenone. Interestingly, we observed a consistent tran-
sient decrease in BP and heart rate contemporaneous
with the weekly collection of urine samples from these
animals. The magnitude of the decrease was similar for
all groups of animals and we attribute these changes
to the increased investigator presence during this
procedure.
Renal Excretory Effects of Eplerenone
The effects of eplerenone on body weight, food and
water intake, urine output, and urinary excretion of Na,
Cl, K, and creatinine are shown in Figures 2 and 3.
Baseline data (reported as week 0) from all groups main-
tained with low-salt diet was collected 1 week prior to
administration of eplerenone and to placing animals on
a high- salt diet. Body weight or food intake did not
vary among the groups. Water intake, urine output, and
urinary excretion of Na and Cl were statistically sig-
niﬁcantly greater in the two high-salt diet groups than
in the low-salt diet groups. Eplerenone did not exhibit
natriuretic effects on Dahl SS rats on either a low-salt
or high-salt diet at steady state. Urinary excretion of K
and creatinine were not statistically signiﬁcantly differ-
ent between the groups. In addition, we tested the acute
natriuretic effect of eplerenone in a separate cohort of
age-matched Dahl SS rats and found that eplerenone
elicited a signiﬁcant natriuretic effect in the low-salt diet
condition (24 h urinary Na excretion of 1.92 ± 0.37
mmol/24 h in animals that received low salt diet plus
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Figure 1. Effects of chronic eplerenone treatment on BP and heart rate in Dahl SS rats. Data are mean ± SEM (n = 8 for each group).
Abbreviations: LS - low salt; HS - high salt; Epl - eplerenone. High salt statistically signiﬁcantly increased sBP after 1 week of salt-loading
(p < 0.05, HS alone vs. LS alone). sBP in LS + Epl 100 mg·kg−1d−1 and HS + Epl 100 mg·kg−1d−1 group was statistically signiﬁcantly
lower than the LS alone (since the ﬁrst week of treatment) and HS alone group (since the second week of treatment), respectively
(p < 0.05). Heart rate was statistically signiﬁcantly higher in the HS alone group than the other three groups in the last 3 weeks of the
study (p < 0.05) (color ﬁgure available online).
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Figure 2. Effects of eplerenone on body weight, food intake, water intake, and urine output in Dahl SS rats. Data are mean ± SEM
(n = 8 for each group). Abbreviations: LS - low salt; HS - high salt; Epl - eplerenone. Body weight and food intake were not statistically
signiﬁcantly different among all groups. Water intake and urine output were statistically signiﬁcantly greater in the two high-salt diet
groups than that in the two low-salt diet groups (*p < 0.05, HS groups vs. LS groups) (color ﬁgure available online).
eplerenone 100 mg·kg−1d−1 vs. 1.26 ± 0.34 mmol/24
h in animals that received low salt diet alone, n = 5
per group, p < 0.05). However, under conditions of
high-salt intake, sodium excretion was equivalent (P
> 0.05) in control animals (9.24 ± 1.61 mmol/24 h,
n = 5) and those that received eplerenone (9.35 ±
0.59 mmol/24 h, n = 5). Urinary protein excretion was
markedly increased in Dahl SS rats on the high-salt
diet, which was signiﬁcantly attenuated (p < 0.05) with
eplerenone after treatment for 7 to 8 weeks (Figure 4).
Biomarkers of Kidney Injury
Urinary LPN and OPN are biomarkers of renal tubular
epithelial injury. KIM-1, also known as TIM-1 (T cell
immunoglobulin mucin domains–1), is a protein that is
predominately expressed in proximal tubules and is a
sensitive biomarker for proximal tubular injury. RPA-
1 is considered as a collecting duct/renal papilla injury
biomarker. All these biomarkers were increased as early
as 2–4 weeks after salt-loading and were signiﬁcantly
diminished by eplerenone treatment towards the end of
the study (Figure 5).
Serum Aldosterone, Plasma Electrolytes, Creatinine,
and Eplerenone Levels
Serum aldosterone levels and plasma Na, K, and crea-
tinine concentrations were not different among groups
(Figure 6 and Table 1). There was a trend towards an
increase in plasma K in those animals that received high
salt plus eplerenone but this did not reach statistical sig-
niﬁcance. The plasma eplerenone concentrations in the
animals that received low salt and high salt were 77.3 ±
11.6 and 90.6 ± 19.4 nM, respectively (Table 2).
Organ Weights and Histopathologic Findings
Animals on the high-salt diet had signiﬁcantly increased
heart and kidney weights, and eplerenone treatment
tended to attenuate these changes (Table 3). Histo-
logic evidence for renal injury was present in rats on
either a low- or high-salt diet but was more severe for
those animals on the high salt diet (Table 4). Thus,
Dahl SS rats on the high-salt diet (Figure 7) exhib-
ited severe focal-segmental or global glomerulosclero-
sis, perivascular ﬁbrosis, inﬂammatory cell inﬁltration,
interstitial ﬁbrosis, tubular dilation, and tubular cast for-
mation, and the quantitative injury scores of glomeruli,
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Figure 3. Effects of Eplerenone on urinary electrolytes and creatinine excretion in Dahl SS rats. Data are mean ± SEM (n = 8 for each
group). Abbreviations: LS - low salt; HS - high salt; Epl - eplerenone. Urinary Na and Cl excretion were statistically signiﬁcantly greater
in the two high-salt diet groups than that in the two low-salt diet groups (*p < 0.05, HS groups vs. LS groups). Urinary K and creatinine
excretion were not statistically signiﬁcantly different among all groups (color ﬁgure available online).
vasculature, interstitium, and renal tubules were signif-
icantly increased. Eplerenone treatment improved the
renal histopathologic alterations induced by salt-loading
(Table 4). With respect to heart collagen content, since
collagen is a normal component of the interstitium,
scores 1 and 2 reﬂect the normal range of histologic
variations; salt-loading for 8 weeks did not signiﬁcantly
increase heart collagen content (Figure 8).
DISCUSSION
Our results demonstrate that Dahl SS rats exhibit a
slow progression of hypertension when maintained on
a low-salt diet, and consumption of a high-salt diet
markedly accelerated the development of hypertension.
Eplerenone completely blocked and signiﬁcantly atten-
uated the progressive rise in SBP in Dahl SS rats
under low-salt and high-salt conditions, respectively.
This observation concurs with several recent reports
that treatment with eplerenone substantially prevented
the development of high salt-induced hypertension in
Dahl SS rats (4,7,8). However, in contrast to these ﬁnd-
ings, other investigators reported that eplerenone has
no effects on BP in salt-loaded Dahl SS rats (14,15).
It is possible that differences in experimental protocol
and technique may contribute to these different ﬁnd-
ings. For example, differences in the age of animals
used and in different salt diets employed could inﬂu-
ence the time course and magnitude of the hypertension
and renal injury. As demonstrated here, the BP lower-
ing efﬁcacy of eplerenone is quite different in animals
maintained on low- and high-salt diets. It is well docu-
mented that long-term exposure to a high-salt diet from
a young age provokes severe hypertension and organ
damage (14,15), which may be refractory to mineralo-
corticoid antagonism. A second possible explanation for
the different effects of eplerenone on BP in this and
other studies could be related to the techniques used
to measure BP. We employed radiotelemetry, generally
viewed as the ‘‘gold standard’’ for BP measurement
(33), in conscious freely moving animals. However,
studies that used the indirect tail cuff plethysmographpy
(14,15) carry limitations in accuracy and do not mon-
itor BP during an entire 24-h period such that minor
differences in BP could have been missed. Finally, the
doses of eplerenone used by Ohtani et al. (14) (12.5
or 40 mg·kg−1d−1) and Nagata et al. (15) (30 or 100
mg·kg−1d−1) could be below those required for BP
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Figure 4. Time course of 24-h urinary protein excretion. Data are
mean ± SEM (n = 8 for each group). Abbreviations: LS - low
salt; HS - high salt; Epl - eplerenone. Urinary protein excretion
was statistically signiﬁcantly greater in the HS alone group than
that in the LS alone group (*p < 0.05, HS alone vs. LS alone).
Proteinuria was statistically signiﬁcantly reduced in the HS + Epl
100 mg·kg−1d−1 group compared with the HS alone group in
the 7th and 8th week of the study (†p < 0.05, HS + Epl 100
mg·kg−1d−1 vs. HS alone) (color ﬁgure available online).
lowering and plasma exposure data for eplerenone were
not provided in their studies. It is important to note
that in our study, eplerenone was administered con-
comitantly with salt-loading at adult age, and the salt
content is lower than that employed in most of the
reports (4,7,14,15).
With respect to mechanism of action, it is sug-
gested that MR antagonists lower BP via enhanced
natriuresis/diuresis or nonrenal mechanisms, including
antagonizing MR in the central nervous system or car-
diovascular tissues (34–37). In the present study, no
natriuretic/diuretic effect of eplerenone was detected
under either low-salt or high-salt conditions by weekly
monitoring of renal excretory function. We suspect
that an early effect on natriuresis/diuresis could have
been missed by assessing renal excretory function after
eplerenone had been administered for 1 week. Accord-
ingly, we performed an acute study with eplerenone
(100 mg·kg−1d−1 for 3 days) in age-matched Dahl SS
rats (without telemetry device implantation), and deter-
mined a signiﬁcant natriuretic effect on the ﬁrst day of
treatment in the low-salt diet condition but not in the
high-salt diet condition. The initial natriuretic/diuretic
effect of eplerenone in animals on a low-salt diet could
lead to a leftward shift of the steady state pressure-
natruresis relationship curve, whereby sodium balance
is maintained at a lower BP level. It is notable that the
BP lowering effect of eplerenone in animals on a high-
salt diet is quite different from the effect seen in animals
on a low-salt diet, and the anti-hypertensive effect of
eplerenone in high-salt fed animals cannot be explained
by acute changes in natriuresis/diuresis. However, the
contributions of nonrenal mechanisms such as antago-
nizing MR in the brain, heart, and vasculature to its BP
efﬁcacy remain to be determined.
The second purpose of the present study was to
evaluate the effects of eplerenone on organ damage.
It is interesting that Dahl SS rats, even on a low-
salt diet, developed proteinuria. This effect may be
attributed to the glomerular phenotype (loss of foot pro-
cesses in podocytes) of this rat strain (38). Although
glomerular hypertension could accelerate proteinuria,
the increase in glomerular pressure may not be a dom-
inant contributor to the development of proteinuria in
Dahl SS rats on low salt diet. Accordingly, a mod-
est decrease in BP by eplerenone in Dahl SS rats
on low salt diet, may not decrease urinary protein
excretion. Animals on a high-salt diet developed more
extensive renal injury as demonstrated by increased
kidney injury biomarkers and histopathologic alter-
ations in glomeruli, vasculature, and interstitium. The
kidneys were enlarged, and proteinuria was dramat-
ically accelerated. All the above-mentioned changes
induced by a high-salt challenge were attenuated by
eplerenone treatment. These ﬁndings further support
the concept that eplerenone has renoprotective effects
in salt-sensitive hypertensive renal injuries (7,8). With
respect to cardiac structure and function, it is appar-
ent that a high-salt diet caused cardiac hypertrophy and
increased heart rate; the latter could potentially reﬂect
an early stage of cardiac dysfunction. Chronic treat-
ment with eplerenone signiﬁcantly reduced the cardiac
changes observed in animals on a high-salt diet. Con-
sistent with our ﬁndings, Ohtani et al. (14) and Nagata
et al. (15) observed that salt-loading could induce heart
failure when 8% salt was introduced to 7 weeks old
Dahl SS rats for 5–6 weeks, subsequent treatment with
eplerenone for 7–8 weeks results in attenuation in left
ventricular hypertrophy and heart failure. Thus, MR
antagonism is beneﬁcial to the heart under high-salt
conditions. It is not the scope of the present study to
investigate the mechanism of organ protection afforded
by eplerenone. However, it is reasonable to speculate
that hemodynamic and/or nonhemodynamic, as well
as other direct actions, might contribute to beneﬁcial
effects of eplerenone on tissues. An extensive body of
evidence suggests salt-sensitive hypertension is asso-
ciated with endothelial dysfunction, oxidative stress,
inﬂammation, and ﬁbrosis (28–30), and eplerenone has
been shown to suppress the induction of oxidative stress
(4,7,15), ﬁbrosis/apoptosis, and inﬂammation (7) in
Dahl SS rats fed high-salt diet.
It is generally accepted that high-salt intake sup-
presses the renin-angiotensin system and aldosterone
levels and low-salt intake has the opposite effect (39).
Previous reports showed that salt-loading in Dahl SS
rats reduced plasma aldosterone levels (8,14,15,40);
however, tissue (heart and kidney) levels of aldosterone
(40) or MR mRNA or protein levels of MR (8,14,15)
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Figure 5. Time course of 24-h urinary kidney injury biomarkers. Data are mean ± SEM (n = 8 for each group). Abbreviations: LS - low
salt; HS - high salt; Epl - eplerenone; LPN - lipocalin-2; OPN -osteopontin; KIM-1 -kidney biomarker molecule-1; RPA-1 -renal papillary
antigen 1. All these biomarkers were increased as early as 2–4 weeks after salt-loading and were statistically signiﬁcantly diminished by
eplerenone treatment towards the end of the study. (*p < 0.05, HS alone vs. LS alone; †p < 0.05, HS + Epl 100 mg·kg−1d−1 vs. HS
alone) (color ﬁgure available online).
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were upregulated. These ﬁndings suggested that high
dietary salt evokes inappropriate activation of the local
aldosterone/MR pathway, which may play a causal role
in the development of salt-sensitive hypertension. In
the present study, high dietary salt did not change
serum aldosterone levels, contrary to reports from other
groups (8,14,15,34). The underlying reason for this
divergent ﬁnding is unclear at this stage. However, we
speculate that the blood sampling method and time of
blood collection may affect the measurement of serum
aldosterone. In the present study, blood samples were
collected around 10AM by jugular venepuncture in con-
scious animals. It is known that aldosterone secretion
exhibits circadian rhythm in rats (41,42) and humans
(43,44). Preliminary data (unpublished) from our lab-
oratory indicates that aldosterone levels measured in
conscious animals are at their lowest in the early morn-
ing. In addition, the stress caused by the procedure of
jugular venepuncture in a conscious state might have an
impact on aldosterone secretion. However, it is difﬁcult
to make an appropriate comparison with other pub-
lished studies in which blood collection was conducted
under anesthesia and the timing of the sample collection
was not reported (8,14,15,40). We did not determine
tissue levels of aldosterone in the present study. Inter-
estingly, Bayorh et al. (40) reported that tissue levels of
aldosterone are increased under conditions of high-salt
administration to Dahl SS rats. Thus, it is conceiv-
able that the beneﬁcial effects of eplerenone (hemo-
dynamic or organ protection) may be a consequence
of inhibiting the effects of elevated tissue levels of
aldosterone.
A concern associated with the clinical use of MR
antagonists is hyperkalemia (45). In the present study,
urinary potassium excretion was slightly less in those
animals that received eplerenone but the change did
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Table 1. Plasma creatinine, Na, and K concentration at the end of 8 weeks treatment
Group 1 Group 2 Group 3 Group 4
LS alone LS + Epl 100
mg.kg−1d−1 HS alone HS + Epl 100
mg.kg−1d−1
Creatinine (mg/dl) 0.41±0.04 0.53±0.07 0.57±0.02 0.66±0.11
Na (mmol/l) 141.2±0.83 141.6±0.81 143.3±0.91 142.9±1.40
K (mmol/l) 5.22±0.17 4.93±0.13 5.12±0.18 5.52±0.12
Abbreviations: LS - low salt; HS - high salt; Epl - eplereneone. Data are mean ± SEM (n = 8i ne a c hg r o u p ) .
Table 2. Plasma eplerenone level at the end of an 8-week treatment
Group Eplerenone Level*
low salt + eplerenone 100 mg·kg−1d−1 77.3 ± 11.6 nM
high salt + eplerenone 100 mg·kg−1d−1 90.6 ± 19.4 nM
Data are mean ± SEM (n = 8i ne a c hg r o u p ) .
*Plasma eplerenone level at 3—4 h after food was removed.
Table 3. Body and organ weights
Group 1 Group 2 Group 3 Group 4
LS alone LS + Epl 100
mg·kg−1d−1 HS alone HS + Epl 100
mg·kg−1d−1
BW, g 495.4±11.9 488.1±7.7 486.5±7.1 480.4±4.8
HW, g 1.94±0.03 1.78±0.04* 2.05±0.04* 1.95±0.04
KW, g 3.59±0.12 3.59±0.07 4.51±0.21* 4.16±0.20
HW/BW, mg/g 3.92±0.09 3.64±0.11 4.22±0.09* 4.06±0.10
KW/BW, mg/g 7.24±0.14 7.36±0.09 9.26±0.35* 8.66±0.39
Abbreviations: LS - low salt; HS - high salt; Epl - eplereneone; BW - body weight; HW - heart weight; KW - kidney weight. Data
are mean ± SEM (n = 8i ne a c hg r o u p ) .* p< 0.05 vs. LS alone.
not reach statistical signiﬁcance. Furthermore, plasma
potassium levels were not statistically different among
groups, although there was a trend for an increase
in plasma potassium for those animals on a high-salt
diet with eplerenone treatment. The somewhat modest
effect on urinary potassium excretion and the absence
of elevated plasma aldosterone in these studies may
both be a consequence of submaximal MR blockade.
Although we do not have a direct in-vivo measure of
the extent of receptor blockade achieved, we do know
that we achieved plasma levels of eplerenone of less
than 100 nM (77.3 nM in animals on a low-salt diet
and 90.6 nM in animals on a high-salt diet). Published
data (37) indicated that in rats, the IC50 of eplerenone
for the aldosterone receptor was 360 nM. Thus, plasma
levels of eplerenone of less than 100 nM would not be
expected to produce complete receptor blockade, which
may account for the minimal changes in potassium
excretion and little change in the plasma concentra-
tion of aldosterone. Furthermore, it is also possible that
higher doses of eplerenone, and hence higher plasma
exposure, could produce a greater extent of BP lowering
and organ protection.
In conclusion, the ﬁndings of the present study
demonstrate that MR antagonism attenuates the
development and progression of hypertension and
provides target organ protection in a model of salt-
sensitive hypertension. Importantly, these data further
support the promise of MR antagonists for the treat-
ment of hypertension.
Table 4. Renal histopathologic scores
Group 1 Group 2 Group 3 Group 4
LS alone LS + Epl 100
mg.kg−1d−1 HS alone HS + Epl 100
mg.kg−1d−1
Tubules 2.0 ±0.1 1.5±0.2 2.9±0.2* 2.4±0.1†
Interstitium 1.3±0.2 1.3±0.2 2.2±0.1* 1.7±0.1†
Vasculature 0.5±0.1 0.5±0.2 2.3±0.3* 0.9±0.3†
Glomeruli 0.6±0.1 0.7±0.3 2.2±0.3* 1.0±0.2†
Abbreviations: LS - low salt; HS - high salt; Epl - eplereneone. Data are mean ± SEM (n = 8i ne a c hg r o u p ) .
*p < 0.05 vs. LS alone; †p < 0.05 vs. HS alone.
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Figure 7. Representative light microscopic ﬁndings in glomeruli, renal tubules, interstitium, and vasculature. Upper panel: HS alone,
glomerulus, renal tubules, interstitium, and renal artery (left→right). Lower panel: HS + Epl 100 mg·kg−1d−1, glomerulus, renal tubules,
interstitium, and renal artery (left→right). High salt alone group shows excess mesangium and decreased capillary lumen in glomeru-
lus, dilated tubules ﬁlled with proteinaceous materials, subendothelial ﬁbrinoid material and endothelial proliferation in renal artery, and
interstitium inﬁltration with mononuclear inﬂammatory cells. HS + Epl 100 mg·kg−1d−1 group exhibits normal appearance of glomeru-
lus, decreased dilation and proteinaceous content in renal tubules, normal vascular appearance, and no inﬁltration with mononuclear
inﬂammatory cells in interstitium (color ﬁgure available online).
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Figure 8. Heart collagen content in all groups. Abbreviations: LS
- low salt; HS - high salt; Epl - eplerenone. Heart collagen content
was not statistically signiﬁcantly different among all groups (color
ﬁgure available online).
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